Display options
Cite
Sulica R, Cefali F, Motschwiller C, et al. COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City. Diagnostics (Basel). 2021;11(1)doi: 10.3390/diagnostics11010128.
Sulica, R., Cefali, F., Motschwiller, C., Fenton, R., Barroso, A., & Sterman, D. (2021). COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City. Diagnostics (Basel, Switzerland), 11(1), . https://doi.org/10.3390/diagnostics11010128
Sulica, Roxana, et al. "COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City." Diagnostics (Basel, Switzerland) vol. 11,1 (2021). doi: https://doi.org/10.3390/diagnostics11010128
Sulica R, Cefali F, Motschwiller C, Fenton R, Barroso A, Sterman D. COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City. Diagnostics (Basel). 2021 Jan 15;11(1). doi: 10.3390/diagnostics11010128. PMID: 33467533; PMCID: PMC7829711.
Copy Download .nbib Format: NLM
Share it on

Diagnostics (Basel). 2021 Jan 15;11(1). doi: 10.3390/diagnostics11010128.

COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City.

Diagnostics (Basel, Switzerland)

Roxana Sulica, Frank Cefali, Caroline Motschwiller, Rebecca Fenton, Anabela Barroso, Daniel Sterman

Affiliations

  1. Department of Medicine, Pulmonary Critical Care and Sleep Division, New York University Grossman School of Medicine, New York University Langone Health, 462 1st Avenue CD 676, New York, NY 10016, USA.

PMID: 33467533 PMCID: PMC7829711 DOI: 10.3390/diagnostics11010128

Abstract

Information on outcomes of COVID-19 in pulmonary arterial hypertension (PAH) patients is limited to a few case series and surveys. Here, we describe our experience at a large Pulmonary Hypertension Center in New York City at the height of the pandemic. We performed a retrospective chart review of eleven consecutive PAH patients who were diagnosed with SARS-CoV-2 infection. We analyzed demographics, PAH severity, risk factors for COVID-19, and COVID-19 severity and outcomes. We found in our sample that 63.6% of patients required intensive care, and there was a 45.45% overall mortality. Most patients had a known COVID-19 contact and mean duration of symptoms prior to presentation was 12 days. Only 4/11 (36%) patients presented to a center with pulmonary hypertension expertise, all of whom survived. Most patients had at least moderate pulmonary hypertension with an average REVEAL score of 7.81 despite double or triple PAH therapy. Our cases series underscores the gravity of SARS-CoV-2 infection in patients with PAH. It also suggests possible interventions to prevent unfavorable outcomes such as preserving social distancing, PAH management optimization, and early and preferential presentation to a center with specialized expertise in PAH.

Keywords: COVID-19; SARS-CoV-2; clinical outcomes; pulmonary arterial hypertension

References

  1. Rev Esp Cardiol. 2020 Sep;73(9):775-778 - PubMed
  2. Am J Respir Crit Care Med. 2011 Nov 15;184(10):1114-24 - PubMed
  3. Diagnostics (Basel). 2020 Jul 31;10(8): - PubMed
  4. Pulm Circ. 2020 May 14;10(2):2045894020925761 - PubMed
  5. Pulm Circ. 2020 Apr 27;10(2):2045894020922799 - PubMed
  6. Lancet. 2020 Feb 15;395(10223):497-506 - PubMed
  7. ERJ Open Res. 2020 Nov 02;6(4): - PubMed
  8. Eur Respir J. 2011 Aug;38(2):359-67 - PubMed
  9. Respir Med Res. 2020 Nov;78:100781 - PubMed
  10. Arch Bronconeumol. 2020 Nov;56(11):749-752 - PubMed
  11. N Engl J Med. 2020 Jun 11;382(24):2372-2374 - PubMed
  12. Pulm Circ. 2020 Sep 21;10(3):2045894020956581 - PubMed
  13. Ann Am Thorac Soc. 2020 Dec;17(12):1576-1582 - PubMed
  14. Pulm Circ. 2020 Jul 23;10(3):2045894020941682 - PubMed
  15. Respir Med. 2020 Jan;161:105850 - PubMed
  16. Pulm Circ. 2020 Apr 29;10(2):2045894020920153 - PubMed

Publication Types